Vivoryon Therapeutics NV (FRA:05Y) Debt-to-Asset : 0.00 (As of Dec. 2023)

Vivoryon Therapeutics NV Debt-to-Asset Chart

Vivoryon Therapeutics NV Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Debt-to-Asset		Get a 7-Day Free Trial					0.01	0.01	0.01	-	-

Vivoryon Therapeutics NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	-	-	-

Competitive Comparison of Vivoryon Therapeutics NV's Debt-to-Asset

For the Biotechnology subindustry, Vivoryon Therapeutics NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's Debt-to-Asset falls into.

Vivoryon Therapeutics NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Vivoryon Therapeutics NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Vivoryon Therapeutics NV's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV  (FRA:05Y) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Vivoryon Therapeutics NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV (FRA:05Y) Business Description